Guardant Health (NASDAQ:GH) Price Target Raised to $130.00

Guardant Health (NASDAQ:GH) had its price target boosted by JPMorgan Chase & Co. from $120.00 to $130.00 in a research note released on Friday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Other analysts have also issued research reports about the company. Leerink Partners lifted their price objective on Guardant Health from $115.00 to $155.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Barclays reaffirmed an “overweight” rating and issued a $130.00 target price on shares of Guardant Health in a research report on Friday. Wells Fargo & Company lifted their price target on shares of Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a report on Thursday, January 22nd. Finally, Canaccord Genuity Group increased their price objective on shares of Guardant Health from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Friday. Twenty-one research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Guardant Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $117.43.

Guardant Health Stock Performance

Shares of GH opened at $103.10 on Friday. The company has a 50-day simple moving average of $106.69 and a 200-day simple moving average of $86.51. The firm has a market capitalization of $13.52 billion, a P/E ratio of -31.15 and a beta of 1.63. Guardant Health has a 52 week low of $34.88 and a 52 week high of $120.74.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The company had revenue of $281.27 million during the quarter, compared to analyst estimates of $269.74 million. During the same quarter in the previous year, the business posted ($0.62) earnings per share. The firm’s quarterly revenue was up 39.4% compared to the same quarter last year. As a group, equities analysts forecast that Guardant Health will post -2.9 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Terilyn J. Monroe sold 8,571 shares of the company’s stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $114.09, for a total value of $977,865.39. Following the sale, the insider owned 20,990 shares of the company’s stock, valued at approximately $2,394,749.10. This represents a 28.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Medina Manuel Hidalgo sold 1,250 shares of the stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $105.00, for a total transaction of $131,250.00. Following the sale, the director owned 797 shares of the company’s stock, valued at $83,685. This trade represents a 61.06% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 434,511 shares of company stock worth $45,580,887 in the last three months. Company insiders own 6.10% of the company’s stock.

Institutional Trading of Guardant Health

Several hedge funds have recently modified their holdings of the company. Alyeska Investment Group L.P. acquired a new position in shares of Guardant Health in the 3rd quarter worth approximately $114,421,000. Price T Rowe Associates Inc. MD increased its holdings in Guardant Health by 33.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after purchasing an additional 1,414,441 shares in the last quarter. Norges Bank bought a new position in Guardant Health in the 4th quarter valued at $128,499,000. Franklin Resources Inc. raised its position in Guardant Health by 78.2% in the 2nd quarter. Franklin Resources Inc. now owns 2,319,947 shares of the company’s stock valued at $120,730,000 after purchasing an additional 1,018,144 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in Guardant Health by 27.3% in the second quarter. Invesco Ltd. now owns 3,558,501 shares of the company’s stock worth $185,184,000 after purchasing an additional 763,834 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

More Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Multiple brokerages raised price targets and maintained buy/overweight ratings (Leerink to $180, JPMorgan to $130, Wells Fargo to $125, BTIG to $145, Canaccord to $135), signaling analyst confidence in upside from current levels. Analyst Raises Coverage
• Positive Sentiment: Q4 revenue beat and strong growth: Guardant reported $281.3M in Q4 revenue, +39% YoY and above consensus; management issued FY2026 revenue guidance around $1.3B, above Street expectations — a growth signal for core oncology testing. Press Release
• Positive Sentiment: Research coverage expansion: Robert W. Baird initiated coverage, which can broaden institutional interest and trading liquidity. Coverage Start
• Neutral Sentiment: Conference call and transcript available — provides detail on cadence of test volume, reimbursement progress and product roadmap; useful for digging into guidance assumptions. Earnings Transcript
• Neutral Sentiment: Market materials (slide deck, press release) posted for investors to verify segment trends and margin assumptions. Slide Deck / Press Release
• Neutral Sentiment: Short-interest data flagged a “significant increase” entry but shows 0 shares / NaN in the feed — the published data appears inconsistent, so short-interest impact is unclear. Short Interest Note
• Negative Sentiment: EPS miss: GAAP loss of ($0.50) vs. consensus (~($0.43)), which disappointed some investors despite revenue upside and may have pressured the stock near the close. Earnings Reaction
• Negative Sentiment: Management left EPS guidance effectively blank in the release (revenue guidance given but no numeric EPS target), which can create uncertainty around near-term profitability expectations. Guidance Details

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.